ArticleArchives of public health = Archives belges de sante publique2025
Sociodemographic index-age differences in the global prevalence of cardiovascular diseases, 1990-2019: a population-based study.
Article in Archives of public health = Archives belges de sante publique, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Global prevalence and mortality of cardiovascular disease by sex and sociodemographic index in young adults (20-39 years): Global burden of disease database 1990-2023.American journal of preventive cardiology · 2026Article
- Global, regional, and national burden and trends of neonatal encephalopathy.Pediatric research · 2026Article
- Disparities in Atrial Fibrillation Metabolic Risk in Indonesia: Time for Sociodemographic Targeted Interventions.JACC. Asia · 2026Article
- Trajectories of healthy lifestyles score and cardiovascular disease: a cohort study.Family medicine and community health · 2026Article
- The Promise and Challenges of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Periodontal Disease.Pathogens (Basel, Switzerland) · 2026Review
- A comparative study of EQ-5D-5L and SF-6D scales based on patients receiving oral anticoagulant therapy.Health and quality of life outcomes · 2026Article
- Combined effect of triglyceride-glucose index and glucose disposal rate on cardio-cerebrovascular disease.PloS one · 2026Article
- The global, regional, and national burden of non-rheumatic degenerative mitral valve disease from 1990 to 2021 and forecast for 2050.Frontiers in cardiovascular medicine · 2026Article
- Dynamic versus Static Metabolic Models for Predicting ECG-Defined Cardiovascular Risk in Elderly MAFLD: A Three-Year Cohort Study.Clinical interventions in aging · 2026Article
- Temporal trends in acute coronary syndrome among women and association with socioeconomic factors-evidence from a middle-income country.Frontiers in global women's health · 2026Article
- Impact of dynamic changes in pain on cardiovascular disease in Chinese middle and elderly people: results from China Health and Retirement Longitudinal Study (CHARLS).BMC public health · 2025Article
- Sociodemographic and sex differences in the global burden of hypertensive heart disease, 1990-2021: a population-based analysis.Tropical medicine and health · 2025Article
- Cardiovascular Disease Attributable to High Systolic Blood Pressure in Younger Adults Requires Greater Attention: Insights from the Global Burden of Disease Study 2021.Journal of the American Heart Association · 2025Article
- Estimation of economic burden of high salt intake in cardiovascular disease attributed to hypertension in Iran.Cost effectiveness and resource allocation : C/E · 2025Article
- Association between residual cholesterol and vulnerable non-culprit lesions progressing to major adverse cardiovascular events.Frontiers in endocrinology · 2025Observational
- Global, regional, and national burden of cardiovascular disease attributable to high body mass index from 1990 to 2021 and projection to 2045.Frontiers in endocrinology · 2025Article
- Global burden of polycystic ovary syndrome among women of childbearing age, 1990-2021: a systematic analysis using the global burden of disease study 2021.Frontiers in public health · 2025Article
- The global, regional, and national patterns of change in the burden of edentulism, 1990-2021: an analysis of the global burden of disease study 2021 and forecast to 2041.Frontiers in oral health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to assess the global burden and trends in cardiovascular diseases (CVDs) prevalence, stratified by sociodemographic index (SDI) categories and age groups, across 204 countries and territories.
methodsUtilizing data from the Global Burden of Disease Study 2019, this study analyzed trends in the age-standardized prevalence rate of overall and type-specific CVDs, including rheumatic heart disease, ischemic heart disease, stroke, hypertensive heart disease, non-rheumatic valvular heart disease, cardiomyopathy and myocarditis, atrial fibrillation and flutter, peripheral artery disease, endocarditis, and other cardiovascular and circulatory diseases. Age-standardized prevalence rates were stratified by SDI categories (low, low-middle, middle, high-middle, and high) and age groups (0-14, 15-49, 50-69, and ≥ 70 years). The corresponding average annual percentage change was calculated to assess temporal trends.
resultsFrom 1990 to 2019, the global age-standardized prevalence rate per 100,000 population for CVD decreased from 6728.04 (95% UI 6394.55 to 7059.66) to 6431.57 (95% UI 6109.95 to 6759.8), with an average annual percent change of -0.15% (95% CI -0.17 to -0.13). When stratified by SDI category, the age-standardized prevalence rate of CVD decreased significantly in high-middle and high SDI countries but increased in middle, low-middle, and low SDI countries. By age group, the age-standardized prevalence rate of CVD declined in the 50-69 and ≥ 70 years groups but increased in the 0-14 and 15-49 years groups. SDI levels were negatively associated with faster increases in the age-standardized prevalence rate of CVD across all ages and age groups. Low SDI countries consistently showed the highest age-standardized prevalence rates of CVD in the younger age groups (0-14 and 15-49 years), while high-middle SDI countries had the highest rates in the older age groups (50-69 and ≥ 70 years). The age-standardized prevalence rate of CVD was negatively associated with SDI levels in the 0-14 and 15-49 years groups and positively associated with SDI levels in the 50-69 and ≥ 70 years groups. Type-specific CVDs such as rheumatic heart disease, other cardiovascular and circulatory diseases, non-rheumatic valvular heart disease, and hypertensive heart disease showed increased age-standardized prevalence rates from 1990 to 2019.
conclusionsThis study highlights significant disparities in CVD prevalence across sociodemographic and age groups. While the global prevalence of CVD has generally decreased, the rise in CVD prevalence in lower SDI countries and younger populations calls for tailored intervention strategies. Addressing these disparities is crucial to mitigating the growing burden of CVD and promoting cardiovascular health on a global scale.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.